Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
February 2006
2006:
December |
November |
October |
September |
August |
July |
June |
May |
April |
March |
February |
January
Other years: 2002 | 2003 | 2004 | 2005 | 2007 | 2008
News | News in brief | News Features
News
US scientists fight political meddling
The rift between US scientists and the administration of President George W. Bush widened last weekend, as Nobel-prizewinning biologist David Baltimore attacked the government's suppression of research findings.
Nature (23 February 2006)
| Full Text |
Frosty US visa policy leaves Indian science cold
India's scientific community is in a bitter mood following the United States' failure to give a visa to a leading Indian organic chemist on the suspicion that his work could be related to chemical warfare.
Nature (23 February 2006)
| Full Text |
Unrest returns to confront Harvard president
Harvard University's president Larry Summers is facing a fresh challenge to his leadership that some say could further undermine his ability to lead the institution.
Nature (23 February 2006)
| Full Text |
Disgraced cloner's ally is cleared of misconduct
Gerald Schatten, the Western face of Woo Suk Hwang's stem-cell team, has been cleared of misconduct by his university, but chided for taking so much credit for research in which he was barely involved.
Nature (16 February 2006)
| Full Text |
Biomedicine to sell itself as a local hero
Lobbyists for biomedical science are tailoring their arguments to local economic issues in an attempt to reverse what they see as a worrying decline in funding.
Nature (16 February 2006)
| Full Text |
Prestige is factored into journal ratings
Researchers propose a new journal ranking scheme which not only measures the number of citations per paper, but also the significance of those citations.
Nature (16 February 2006)
| Full Text |
Doubts hang over source of bird flu spread
Although migratory birds have been widely blamed for the spread of H5N1, some believe that the risks posed by the poultry trade are being overlooked.
Nature (16 February 2006)
| Full Text |
Political strife set to delay EU funds
A power struggle between the European Parliament and member states of the European Union (EU) threatens to delay the start date of the EU's next funding program for research.
Nature (09 February 2006)
| Full Text |
Journal lays bare remarks from peer reviewers
By publishing signed reviews alongside papers, the editors of a new journal hope to make the process of peer review more transparent and improve the quality of the articles.
Nature (09 February 2006)
| Full Text |
Earlier drug tests on people could be unsafe, critics warn
The FDA has set new guidelines to speed up drug development, but critics say they might expose research participants to unwarranted danger.
Nature Medicine (February 2006)
| Full Text |
New law offers drug makers sweeping protection against lawsuits
Pharmaceutical companies will not be liable if someone who took its products during a public health emergency, such as an avian flu outbreak or a bioterrorism attack, were to become ill or die.
Nature Medicine (February 2006)
| Full Text |
Side benefits sway developing nations to choose unneeded vaccines
Global health agencies may be backing vaccines for low-prevalence diseases and drawing the focus away from more pressing health problems, critics charge.
Nature Medicine (February 2006)
| Full Text |
New York's scheme to track diabetes stirs privacy concerns
A massive project to track people with diabetes through a city-wide database has raised concerns about privacy and a clear lack of informed consent.
Nature Medicine (February 2006)
| Full Text |
Powerful new database pins down emerging infections
A massive new database promises to help scientists identify and fight emerging viruses.
Nature Medicine (February 2006)
| Full Text |
Australia considers changing laws to allow therapeutic cloning
A government-commissioned review has recommended changes to existing laws that permit the creation of new stem cell lines from excess embryos to allow therapeutic cloning.
Nature Medicine (February 2006)
| Full Text |
China offers alternative gateway for experimental drugs
Several experimental biologic drugs pioneered by Western biotech companies that failed to reach the US or European markets have recently been approved in China.
Nature Biotechnology (February 2006)
| Full Text |
Nanomedicine lacks recognition in Europe
A recent report by the European Science Foundation (ESF) claims that nanomedicine still lacks an adequate funding structure.
Nature Biotechnology (February 2006)
| Full Text |
Doubts over biochemist's data expose holes in Japanese fraud laws
A committee set up by the University of Tokyo has concluded that an experiment published by biochemist Kazunari Taira is not reproducible.
Nature (02 February 2006)
| Full Text |
Experts plan to reclaim the web for pop science
A coalition of science agencies and Silicon Valley entrepreneurs are launching what they claim will be an authoritative network of websites.
Nature (02 February 2006)
| Full Text |
Senators seek cash to save US science
The United States is losing its scientific edge and needs billions of extra dollars to rekindle innovation, according to a bipartisan group of US senators.
Nature (02 February 2006)
| Full Text |
Stem-cell tagging shows flaws
A team led by Catherine Verfaillie at the University of Minnesota, is raising a red flag over the use of thymidine labeling to examine the behavior of transplanted stem cells.
Nature (02 February 2006)
| Full Text |
Should journals police scientific fraud?
Editors don't expect peer review to catch deliberate fakers, but recent scandals mean that journals are looking at other ways to detect fabricated papers.
Nature (02 February 2006)
| Full Text |
Forensic software traces tweaks to images
The editors of scientific journals could catch fraudulent images by using computer tools similar to those being developed for law enforcement and photojournalism.
Nature (02 February 2006)
| Full Text |
News in brief
Ohio closes the door on intelligent design in schools
| Scripps Florida will be built away from wildlife refuge
| US academies to set up panel for stem-cell ethics
| NIH urged to enforce its public-access policy
| US targets roles of genes and environment in disease
| Boston biosafety lab gets all-clear for construction
| Fall-out over faked clones continues to shake Korea
| Depression drugs safe, says new study
| Terrorist attack spooks Indian scientists
| Norway set to push law to punish scientific fraud
| Phase 0 clinical trials
| WTO gives poor states access to drugs
| Genzyme strides into gene therapy
| Doctors attack constraints on access to patients' data
News Features
Protein purification: Fast forward
Technologies well adapted to isolate individual proteins get a makeover to tackle large numbers of samples.
Nature (23 February 2006)
| Full Text |
Virtual globes: The web-wide world
Online tools, led by the Google Earth virtual globe, are changing the way we interact with spatial data.
Nature (16 February 2006)
| Full Text |
Medical research: Them and us no longer
Scientists and medical doctors view research through different lenses — but the gulf in outlook between the two tribes isn't what it used to be.
Nature (16 February 2006)
| Full Text |
Cloning: Mining the secrets of the egg
After the collapse of Hwang's claims, researchers are returning to the drawing board to see whether anyone can make patient-matched cells at all.
Nature (09 February 2006)
| Full Text |
Cloning: Do we even need eggs?
Will we need therapeutic cloning at all, if immunologists can stop our bodies fighting transplants?
Nature (09 February 2006)
| Full Text |
The scientific balance of power
The world's most advanced economies are losing their scientific edge, some analysts claim.
Nature (09 February 2006)
| Full Text |
Where the chips fall
Genetic chips that promise to predict the outcome of cancer are rushing into the market. But are they reliable?
Nature Medicine (February 2006)
| Full Text |
The second wave in kinase cancer drugs
Cancer drugs targeting signaling pathways have been hampered by problems of efficacy and tumor resistance. Will the next generation of kinase inhibitors fare better than the first?
Nature Biotechnology (February 2006)
| Full Text |
Lyme disease: Uphill Struggle
The first vaccine against Lyme disease was withdrawn because patients distrusted it. Should market forces be allowed to shape the next one?
Nature (02 February 2006)
| Full Text |
|
